首页 >研究所概况

研究所概况

所况介绍

      上海市肿瘤研究所(以下简称“肿瘤所”)成立于1958年,隶属于上海交通大学医学院。1980年被确认为世界卫生组织癌症预防与控制合作中心。1985年被批准建立癌基因及相关基因国家重点实验室。1996年与上海市科委共建基因治疗研究中试上海基地。2003年与上海交通大学共建上海交通大学肿瘤研究所。2010年,与仁济医院实现院所合一。2019年,隶属关系转至上海市教委,由上海交通大学医学院和仁济医院管理。

      

     目前,全所拥有实验室空间26820平方米,分别位于三个区域,其中徐汇区斜土路7820平方米,浦东仁济科研楼16000平方米,上海交通大学闵行校区3000平方米。设有肿瘤微环境、肿瘤分子病理学、肿瘤流行病研究等16个研究组(室)和8个青年研究组(室)。另设有科研公共平台、《肿瘤》杂志编辑部等科研辅助部门。截止2021年底,共有在编职工150人,其中科技人员132人,有中国工程院院士1人、终身教授1人、长江学者1人。具有高级专业技术职称者30人,博士学历93人,研究生导师32人(博导21人、硕导11人),招生专业为肿瘤学、生物化学与分子生物学、病原生物学等。肿瘤所多次荣获国家和上海市各级人才计划,包括国家杰出青年、国家优秀青年、国家新世纪百千万人才工程、国家万人计划青年拔尖人才、教育部新世纪人才计划、上海市领军人才、上海市优秀学科带头人、上海市曙光学者和上海市东方学者等。

      

       目前,肿瘤所的主要研究方向为恶性肿瘤的流行病学与病因学,肿瘤发病机理及肿瘤细胞免疫治疗等生物高科技研究,探索肿瘤防治的新途径等相关领域。已建成肿瘤干细胞、肿瘤微环境、肿瘤靶向生物治疗、肿瘤分子病理学、肿瘤免疫调节等科学研究技术平台及实验动物研究平台,拥有质谱分析仪、高通量测序仪、激光共聚焦显微镜、小动物活体成像仪、小动物SPECT等先进科研设备,向所内外提供相关的实验设备和服务,并提供实验动物。

      

    “十三五” 至今,肿瘤所发展十分迅速。通过大力推进院所融合,完善科研创新机制,肿瘤所的自主创新能力明显增强,科研成效持续显现,先后产出了一批有影响的重要科研成果。




 49b6899efae82844f632fc2b6443a464_副本.jpg


   

科研项目与成果奖励:新增各类纵向科研项目295项(国家级项目80项),新增科研经费达到了9586万元。其中,包括国自然重点国际(地区)合作研究项目1项,国自然重点项目1项,新增科技部重大专项和重点研发子课题5项。在国家科学自然基金竞争日趋激烈的情况下,通过发挥自身肿瘤基础研究的特色与优势,挖掘青年人员潜力,不断提升项目竞争力,国家自然基金保持了稳定增长,新增NSFC项目80项,新增NSFC项目经费3989万元。


 科研论文:“十三五”至今,全所SCI论文量质齐升,共发表SCI论文257篇,平均影响因子为7.02,其中IF ≥10 的文章54篇。2019年论文首次登上《Nature》主刊,影响因子达到43.07,实现科研新突破。

       

专利和转化:“十三五”至今,共申请发明专利59项,授权专利17项。有4项重要专利成果以不同形式成功获得转化,转让金额达到1206万元,实现了转化医学研究的重要突破,也为肿瘤所后继科研成果转化的机制建设和模式探索起到了良好的示范和带动作用。


人才培养:肿瘤所坚持实施“人才强所”战略,进一步完善人才扶持和激励机制,加大对人才队伍建设的投入力度,“十三五”期间,先后从国内外招录引进83名有潜质的优秀青年人才来所工作,其中包括“东方学者”1名和高水平院校博士63名,有45余人次先后入选了国家和上海市的各类人才计划,其中包括国家优青、国家杰青、国家万人计划青年拔尖人才、上海市优秀学科带头人、上海市领军人才、上海市千人计划、东方学者、上海市青年拔尖人才、上海市人才发展资金、上海市科技启明星和上海市重点人才计划等。现有导师32人(博导21人,硕导11人),十三五期间共招收104名研究生,其中博士49人,共毕业86名研究生,其中上海市优秀毕业生5人,校级优秀毕业生14人,获国家奖学金7人。


国内外学术活动:依托自身的基础研究优势,聚焦肿瘤转化研究的关键领域,肿瘤所先后组织召开和参与了一系列重要国际、国内学术会议,促进了肿瘤所和重点实验室的对外学术交流和合作,提升了在国际肿瘤学术领域的影响。


Shanghai Cancer Institute (hereinafter referred to as "SCI") was established in 1958 and is affiliated to the Shanghai Jiao Tong University School of Medicine. In 1980, it was recognized as the World Health Organization's Cooperative Center for Cancer Prevention and Control. In 1985, it was authorized to found the State Key Laboratory of Oncogenes and Related Genes. SCI set up the gene therapy research pilot test base in Shanghai together with Shanghai Municipal Commission of Science and Technology in 1996 and co-founded the SJTU Cancer Institute with SJTU in 2003. In 2010, SCI was merged with Ren Ji Hospital to form “a unity”. In 2019, the subordination of SCI was transferred to the Shanghai Municipal Education Commission, and SCI was jointly managed by SJTU School of Medicine and Ren Ji Hospital since then.

At present, SCI has a total of 26820 square meters of laboratory space located in three areas, including 7820 square meters of space in Xietu Road in Xuhui District, 16000 square meters of space in Ren Ji Hospital in Pudong New Area and 3000 square meters of space in SJTU in Minhang District. There are 16 research groups and 8 youth research groups focusing on cancer microenvironment research, cancer molecular pathology, cancer epidemiology, etc. In addition, auxiliary departments such as public research platforms, editorial office of Tumor, etc. have been set up to support scientific research. By the end of 2021, there are 150 officially budgeted employees, including 132 scientific researchers, one member of the Chinese Academy of Engineering, one tenured professor and one Changjiang scholar. 30 of them hold a senior professional and technical title, and 93 of them hold a doctoral degree. There are 32 postgraduate supervisors (21 doctoral supervisors and 11 master’s supervisors), and the enrollment programs include oncology, biochemistry and molecular biology, pathogenic biology, etc. SCI has won a collection of national and Shanghai municipal talent awards at all levels, including National Distinguished Young Scholars, National Excellent Youth, National New Century Millions of Talents Project, National Ten Thousand Talents Plan, New Century Talent Plan of the Ministry of Education, Shanghai Outstanding Academic Leaders Plan, Shanghai Excellent Academic/Technology Research Leader Program, Shanghai Dawn Scholars and Shanghai Oriental Scholars, etc.

The current research work of SCI is mainly oriented toward the epidemiology and etiology of malignant cancer, cancer pathogenesis and cancer cell immunotherapy, as well as research fields related to the exploration of new ways of cancer prevention and treatment. Multiple high-tech research platforms and experimental animal research platforms have been established to facilitate researches on cancer stem cells, cancer microenvironment, cancer targeted biotherapy, cancer molecular pathology, cancer immunomodulation, etc. Fully armed with advanced research equipment such as mass spectrometer, high-throughput sequencer, laser confocal microscope, small animal live imager, small animal SPECT, etc., SCI provides experimental equipment and services as well as experimental animals to both internal and external users.

Since the “13th Five Year Plan” period, SCI has gained rapid development. By integrating the institute with hospitals and improving the scientific research innovation mechanism, SCI has shown significantly enhanced ability of independent innovation and continuous research outputs with a number of high-impact research achievements having been produced successively.

Research projects and Awards for scientific achievements: 295 new vertical scientific research projects (including 80 national level projects) have been launched with a 95.86-million increase in funding support for scientific research. Among these projects, there are one Key Program for International (regional) S&T Cooperation Projects of China, one State Key Program of National Natural Science of China, and five new National Science and Technology Major Projects and National Key R&D Program sub-topics of the Ministry of Science and Technology of China. In recent years, SCI has maintained a steady growth in the funding support from NSFC, with 80 more new NSFC projects and 39.89 million more of NSFC project funds approved, under increasingly intensified competition by taking advantage of its advanced basic research in oncology, exploiting the potential of young researchers and enhancing the competitivity of our research projects.

Scientific research papers: The quantity and quality of SCI publication in the Institute have perked up since the "13th Five Year Plan". A total of 257 SCI papers have been published with an average impact factor of 7.02, including 54 papers with IF ≥ 10. In 2019, SCI’s first Nature (IF=43.07) paper was published, marking a new breakthrough in scientific research.

Patents and transformation: Since “the 13th Five Year Plan”, SCI has applied for 59 invention patents and 17 have been granted. Four important patent achievements have been successfully transformed in different forms with the amount of compensation received from patent transfer reaching 12.06 million, which is a major breakthrough in the research of translational medicine and also a good demonstration and driving force in the mechanism construction and mode exploration for the transformation of future research outcomes in SCI.

Talent cultivation: SCI firmly adheres to the strategy of "strengthening the Institute with talents". It has reinforced its effort to the construction of talent teams and improved its talent support and motivation mechanism. During the "13th Five Year Plan" period, 83 outstanding young talents from China and abroad have been recruited to SCI, including one "Oriental Scholar" and 63 PhDs from high-level universities. More than 45 of them have been selected into various national and Shanghai talent plans, including National Outstanding Youth, National Distinguished Young Scholar, National Ten Thousand Talents Program Young Top Talents, Shanghai Excellent Academic/Technology Research Leader Program, Shanghai Outstanding Academic Leaders Plan, Shanghai Thousand Talents Program, Oriental Scholars, Shanghai Young Top Talents, Shanghai Talent Development Fund, Shanghai Rising-Star Program and Shanghai Key Talent Program. At present, SCI has 32 postgraduate supervisors (21 doctoral supervisors and 11 master’s supervisors). During the “13th Five Year Plan” period, 104 postgraduate students, including 49 PhD students, were enrolled, and 86 students, including 5 outstanding graduates in Shanghai, 14 outstanding graduates of the school and 7 national scholarship awardees, graduated.

Domestic and international academic activities: With its advantages in basic research and its focus on the key areas of transformational cancer research, SCI has organized and participated in a series of important international and domestic academic conferences, promoted the academic communication and cooperation of SCI and its state key laboratory with external institutions, and enhanced its international influence in the academic field of cancer research.


ICP备案号:沪ICP备15036656号-1 版权所有:上海市肿瘤研究所